naluzotan naluzotan naluzotan (inn, usan; prx-00023) is a serotonergic drug of the phenylpiperazine class that was under investigation by epix pharmaceuticals inc for the treatment of generalized anxiety disorder and major depressive disorder. it acts as a selective and potent 5-ht1a receptor partial agonist, readily stimulating prolactin responses, though it has also been found to bind to and activate the σ receptor. naluzotan was well tolerated in clinical trials, with more patients in the control group dropping out due to adverse effects than in the active group in one study. the most frequently reported side effect was headache in 15% of patients (compared to 10% for placebo). in addition, naluzotan demonstrated significant antidepressant and anxiolytic effects as per the ham-d and madrs and the ham-a, respectively, in some trials, but in others it did not. in the end it was not found to be significantly superior enough to placebo and development was stopped. naluzotanclinical dataroutes ofadministrationoralatc codenoneidentifiers iupac name n-(3-phenyl)acetamide cas number740873-06-7pubchem cid11430856chemspider9605731uniilq54e5b4ewcomptox dashboard (epa)dtxsid40995527 chemical and physical dataformulac23h38n4o3smolar mass450.64 g·mol−13d model (jsmol)interactive image smiles o=c(nc3cccc(n2ccn(ccccns(=o)(=o)cc1ccccc1)cc2)c3)c inchi inchi=1s/c23h38n4o3s/c1-20(28)25-22-10-7-11-23(18-22)27-16-14-26(15-17-27)13-6-5-12-24-31(29,30)19-21-8-3-2-4-9-21/h7,10-11,18,21,24h,2-6,8-9,12-17,19h2,1h3,(h,25,28)key:spwzxwdpawdkqe-uhfffaoysa-n (verify)